Confluence Genetics Launches Cas-CLEAR™, a New CRISPR Technology Platform for Cancer Therapy
Saved in:
| Title: | Confluence Genetics Launches Cas-CLEAR™, a New CRISPR Technology Platform for Cancer Therapy |
|---|---|
| Authors: | Confluence Genetics |
| Source: | Business Wire (English). 07/09/2026. |
| Abstract: | Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology platform for the treatment of cancers carrying defined genetic signatures, with lead programs in development for hepatocellular carcinoma (HCC). Unlike gene editing CRISPR systems that cut and modify DNA at a single site, Cas-CLEAR uses Cas12a2 nucleases to recognize cancer-specific genetic signatures and trigger broad collateral cleavage of cellular DNA and RNA, resulting in the selective elimination of cells carrying the targeted signature. The launch coincides with two independent Nature publications validating the platform’s selective cancer cell-killing mechanism: a peer-reviewed publication from the laboratory of Nobel laureate Jennifer Doudna at the University of California, Berkeley featuring in vivo mouse model data, and another led by researchers at Utah State University and University of Utah Health. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Confluence Genetics today announced the launch of Cas-CLEAR™, Collaterally Enhanced Activated Ribonuclease, a new CRISPR technology platform for the treatment of cancers carrying defined genetic signatures, with lead programs in development for hepatocellular carcinoma (HCC). Unlike gene editing CRISPR systems that cut and modify DNA at a single site, Cas-CLEAR uses Cas12a2 nucleases to recognize cancer-specific genetic signatures and trigger broad collateral cleavage of cellular DNA and RNA, resulting in the selective elimination of cells carrying the targeted signature. The launch coincides with two independent Nature publications validating the platform’s selective cancer cell-killing mechanism: a peer-reviewed publication from the laboratory of Nobel laureate Jennifer Doudna at the University of California, Berkeley featuring in vivo mouse model data, and another led by researchers at Utah State University and University of Utah Health. [ABSTRACT FROM PUBLISHER] |
|---|
